Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EBITDA | -38.26M | -51.49M | -38.77M | -28.67M | -23.98M | -14.89M |
Net Income | -29.07M | -44.58M | -42.77M | -31.79M | -24.12M | -15.09M |
Balance Sheet | ||||||
Total Assets | 13.70M | 25.47M | 12.08M | 21.59M | 37.20M | 58.66M |
Cash, Cash Equivalents and Short-Term Investments | 11.04M | 23.29M | 9.56M | 19.87M | 35.70M | 57.17M |
Total Debt | 453.51K | 494.00K | 552.98K | 603.83K | 301.74K | 421.64K |
Total Liabilities | 6.23M | 11.18M | 25.85M | 12.05M | 4.16M | 3.86M |
Stockholders Equity | 7.47M | 14.29M | -13.78M | 9.54M | 33.05M | 54.79M |
Cash Flow | ||||||
Free Cash Flow | -34.64M | -47.69M | -33.24M | -25.45M | -22.71M | -14.00M |
Operating Cash Flow | -34.58M | -47.58M | -32.38M | -25.22M | -22.57M | -13.93M |
Investing Cash Flow | -61.29K | -104.19K | -864.04K | -225.97K | -141.36K | -62.35K |
Financing Cash Flow | 19.81M | 61.41M | 22.94M | 9.61M | 1.25M | 60.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.33 | -41.57% | 2.23% | 23.26% | -2.03% | |
49 Neutral | $103.54M | ― | -146.92% | ― | -61.16% | -139.15% | |
48 Neutral | $16.41M | ― | -194.84% | ― | ― | 48.91% | |
40 Underperform | $14.09M | ― | -122.28% | ― | ― | ― | |
34 Underperform | $15.55M | ― | -273.88% | ― | ― | 73.37% | |
34 Underperform | $16.50M | 1.59 | >-0.01% | ― | ― | ― | |
31 Underperform | $11.95M | ― | -183.72% | ― | ― | 20.28% |
On March 12, 2025, Cellectar Biosciences’ board approved amendments to the employment agreements of its CEO and COO, enhancing their severance benefits in the event of a change in control. Additionally, on March 11, 2025, the board adopted new by-laws to align with Delaware law, revising stockholder nomination procedures and reducing the quorum requirement for meetings.